Mechanism of Action: Luspatercept vs Epoetin Alfa in LR-MDS

Saeed Sadeghi, MD, discusses the differing mechanisms of action between luspatercept and epoetin alfa, highlighting how these differences may correlate with clinical benefits for patients with lower-risk myelodysplastic syndromes (LR-MDS).

Now Viewing

EP: 1.Mechanism of Action: Luspatercept vs Epoetin Alfa in LR-MDS

EP: 2.COMMANDS Study Update: Luspatercept vs. Epoetin Alfa in 1L Treatment

EP: 3.Real-World Data on Luspatercept in LR-MDS

EP: 4.Health Care Resource Utilization: Luspatercept vs ESAs in MDS

EP: 5.Current Approach to Treating Anemia in LR-MDS

EP: 6.Future Perspective on Anemia Treatment in LR-MDS

Video content above is prompted by the following:

Please discuss how the mechanism of action differs between luspatercept and epoetin alfa and how it may correlate with clinical benefit for patients with LR-MDS.

Recent Videos